Sickle cell disease is a devastating, inherited blood disorder that affects an estimated eight million people worldwide and ...

At the Cleveland Clinic, doctors are using a one-time gene-editing therapy that alters a patient’s own blood-forming stem cells to correct the genetic mutation responsible for the disease. Physicians ...

The federal government wants to make it easier for Medicaid patients to access new, curative treatments — one of the few initiatives on which President Donald Trump and the public health establishment ...

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...

PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...

A publicly funded consortium of University of California (UC) researchers and clinicians is one big step closer to realizing a decade-long plan to launch a CRISPR-based gene-editing trial for sickle ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up When Dr. Ambroise Wonkam walked into a panel on medical genetics ...